サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1756581

BRAFキナーゼ阻害剤の世界市場 2025年～2029年

Global BRAF Kinase Inhibitors Market 2025-2029

出版日
発行
TechNavio
ページ情報
英文 208 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
BRAFキナーゼ阻害剤の世界市場 2025年～2029年
出版日: 2025年06月11日
発行: TechNavio
ページ情報: 英文 208 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

BRAFキナーゼ阻害剤市場は2024年～2029年に21億6,200万米ドル、予測期間中のCAGRは9％で成長すると予測されます。

当レポートでは、BRAFキナーゼ阻害剤市場の全体的な分析、市場規模・予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、BRAFキナーゼ阻害剤の高い標的親和性と特異性、患者支援プログラムの存在、がんの有病率の増加が牽引しています。

市場範囲
基準年 2025
終了年 2029
予測期間 2025-2029
成長モメンタム 加速
前年比 8%
CAGR 9%
増分額 21億6,200万米ドル

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。レポートには、主要企業の分析に加え、包括的な市場規模データ、地域別分析によるセグメント、ベンダー情勢が含まれています。レポートには過去データと予測データがあります。

本調査では、今後数年間のBRAFキナーゼ阻害剤市場の成長を促進する主な要因の1つとして、BRAFキナーゼ阻害剤における調査分野の拡大を挙げています。また、戦略的提携の拡大やがんに対する意識の高まりは、市場の大きな需要につながるでしょう。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 Technavio分析

  • 価格・ライフサイクル・顧客購入バスケット・採用率・購入基準の分析
  • インプットの重要性と差別化の要因
  • 混乱の要因
  • 促進要因と課題の影響

第3章 市場情勢

  • 市場エコシステム
  • 市場の特徴
  • バリューチェーン分析

第4章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2024
  • 市場の見通し 2024年～2029年

第5章 市場規模実績

  • BRAFキナーゼ阻害剤の世界市場 2019年～2023年
  • 製品別セグメント分析 2019年～2023年
  • 流通チャネル別セグメント分析 2019年～2023年
  • 適応症別セグメント分析 2019年～2023年
  • 地域別セグメント分析 2019年～2023年
  • 国別セグメント分析 2019年～2023年

第6章 定性分析

  • AIの影響： BRAFキナーゼ阻害剤の世界市場

第7章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第8章 市場セグメンテーション：製品別

  • 市場セグメント
  • 比較：製品別
  • ダブラフェニブ：市場規模と予測 2024年～2029年
  • ソラフェニブ：市場規模と予測 2024年～2029年
  • ベムラフェニブ：市場規模と予測 2024年～2029年
  • エンコラフェニブ：市場規模と予測 2024年～2029年
  • 市場機会：製品別

第9章 市場セグメンテーション：流通チャネル別

  • 市場セグメント
  • 比較：流通チャネル別
  • 病院薬局：市場規模と予測 2024年～2029年
  • 小売薬局：市場規模と予測 2024年～2029年
  • オンライン薬局：市場規模と予測 2024年～2029年
  • 市場機会：流通チャネル別

第10章 市場セグメンテーション：適応症別

  • 市場セグメント
  • 比較：適応症別
  • 転移性黒色腫：市場規模と予測 2024年～2029年
  • 転移性肺がん：市場規模と予測 2024年～2029年
  • その他：市場規模と予測 2024年～2029年
  • 市場機会：適応症別

第11章 顧客情勢

  • 顧客情勢の概要

第12章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米：市場規模と予測 2024年～2029年
  • 欧州：市場規模と予測 2024年～2029年
  • アジア：市場規模と予測 2024年～2029年
  • 世界のその他の地域：市場規模と予測 2024年～2029年
  • 米国：市場規模と予測 2024年～2029年
  • ドイツ：市場規模と予測 2024年～2029年
  • 英国：市場規模と予測 2024年～2029年
  • カナダ：市場規模と予測 2024年～2029年
  • 日本：市場規模と予測 2024年～2029年
  • フランス：市場規模と予測 2024年～2029年
  • ブラジル：市場規模と予測 2024年～2029年
  • 中国：市場規模と予測 2024年～2029年
  • インド：市場規模と予測 2024年～2029年
  • イタリア：市場規模と予測 2024年～2029年
  • 市場機会：地域情勢別

第13章 促進要因・課題・機会・抑制要因

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場の機会・抑制要因

第14章 競合情勢

  • 概要
  • 競合情勢
  • 混乱の状況
  • 業界のリスク

第15章 競合分析

  • 企業プロファイル
  • 企業ランキング指数
  • 企業の市場ポジショニング
  • Asana BioSciences LLC
  • Bayer AG
  • BeiGene Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fore Biotherapeutics
  • Jazz Pharmaceuticals Plc
  • Kinnate Biopharma Inc.
  • Nerviano Medical Sciences S.r.l
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Pierre Fabre SA

第16章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibits7: Executive Summary - Chart on Market Segmentation by Indication
  • Exhibits8: Executive Summary - Chart on Incremental Growth
  • Exhibits9: Executive Summary - Data Table on Incremental Growth
  • Exhibits10: Executive Summary - Chart on Company Market Positioning
  • Exhibits11: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits12: Overview on criticality of inputs and factors of differentiation
  • Exhibits13: Overview on factors of disruption
  • Exhibits14: Impact of drivers and challenges in 2024 and 2029
  • Exhibits15: Parent Market
  • Exhibits16: Data Table on - Parent Market
  • Exhibits17: Market characteristics analysis
  • Exhibits18: Value chain analysis
  • Exhibits19: Offerings of companies included in the market definition
  • Exhibits20: Market segments
  • Exhibits21: Chart on Global - Market size and forecast 2024-2029 ($ million)
  • Exhibits22: Data Table on Global - Market size and forecast 2024-2029 ($ million)
  • Exhibits23: Chart on Global Market: Year-over-year growth 2024-2029 (%)
  • Exhibits24: Data Table on Global Market: Year-over-year growth 2024-2029 (%)
  • Exhibits25: Historic Market Size - Data Table on Global BRAF Kinase Inhibitors Market 2019 - 2023 ($ million)
  • Exhibits26: Historic Market Size - Product Segment 2019 - 2023 ($ million)
  • Exhibits27: Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
  • Exhibits28: Historic Market Size - Indication Segment 2019 - 2023 ($ million)
  • Exhibits29: Historic Market Size - Geography Segment 2019 - 2023 ($ million)
  • Exhibits30: Historic Market Size - Country Segment 2019 - 2023 ($ million)
  • Exhibits31: Five forces analysis - Comparison between 2024 and 2029
  • Exhibits32: Bargaining power of buyers - Impact of key factors 2024 and 2029
  • Exhibits33: Bargaining power of suppliers - Impact of key factors in 2024 and 2029
  • Exhibits34: Threat of new entrants - Impact of key factors in 2024 and 2029
  • Exhibits35: Threat of substitutes - Impact of key factors in 2024 and 2029
  • Exhibits36: Threat of rivalry - Impact of key factors in 2024 and 2029
  • Exhibits37: Chart on Market condition - Five forces 2024 and 2029
  • Exhibits38: Chart on Product - Market share 2024-2029 (%)
  • Exhibits39: Data Table on Product - Market share 2024-2029 (%)
  • Exhibits40: Chart on Comparison by Product
  • Exhibits41: Data Table on Comparison by Product
  • Exhibits42: Chart on Dabrafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits43: Data Table on Dabrafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits44: Chart on Dabrafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits45: Data Table on Dabrafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits46: Chart on Sorafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits47: Data Table on Sorafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits48: Chart on Sorafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits49: Data Table on Sorafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits50: Chart on Vemurafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits51: Data Table on Vemurafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits52: Chart on Vemurafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits53: Data Table on Vemurafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits54: Chart on Encorafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits55: Data Table on Encorafenib - Market size and forecast 2024-2029 ($ million)
  • Exhibits56: Chart on Encorafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits57: Data Table on Encorafenib - Year-over-year growth 2024-2029 (%)
  • Exhibits58: Market opportunity by Product ($ million)
  • Exhibits59: Data Table on Market opportunity by Product ($ million)
  • Exhibits60: Chart on Distribution Channel - Market share 2024-2029 (%)
  • Exhibits61: Data Table on Distribution Channel - Market share 2024-2029 (%)
  • Exhibits62: Chart on Comparison by Distribution Channel
  • Exhibits63: Data Table on Comparison by Distribution Channel
  • Exhibits64: Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
  • Exhibits65: Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
  • Exhibits66: Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
  • Exhibits67: Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
  • Exhibits68: Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
  • Exhibits69: Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
  • Exhibits70: Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
  • Exhibits71: Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
  • Exhibits72: Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
  • Exhibits73: Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
  • Exhibits74: Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
  • Exhibits75: Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
  • Exhibits76: Market opportunity by Distribution Channel ($ million)
  • Exhibits77: Data Table on Market opportunity by Distribution Channel ($ million)
  • Exhibits78: Chart on Indication - Market share 2024-2029 (%)
  • Exhibits79: Data Table on Indication - Market share 2024-2029 (%)
  • Exhibits80: Chart on Comparison by Indication
  • Exhibits81: Data Table on Comparison by Indication
  • Exhibits82: Chart on Metastatic melanoma - Market size and forecast 2024-2029 ($ million)
  • Exhibits83: Data Table on Metastatic melanoma - Market size and forecast 2024-2029 ($ million)
  • Exhibits84: Chart on Metastatic melanoma - Year-over-year growth 2024-2029 (%)
  • Exhibits85: Data Table on Metastatic melanoma - Year-over-year growth 2024-2029 (%)
  • Exhibits86: Chart on Metastatic lung cancer - Market size and forecast 2024-2029 ($ million)
  • Exhibits87: Data Table on Metastatic lung cancer - Market size and forecast 2024-2029 ($ million)
  • Exhibits88: Chart on Metastatic lung cancer - Year-over-year growth 2024-2029 (%)
  • Exhibits89: Data Table on Metastatic lung cancer - Year-over-year growth 2024-2029 (%)
  • Exhibits90: Chart on Others - Market size and forecast 2024-2029 ($ million)
  • Exhibits91: Data Table on Others - Market size and forecast 2024-2029 ($ million)
  • Exhibits92: Chart on Others - Year-over-year growth 2024-2029 (%)
  • Exhibits93: Data Table on Others - Year-over-year growth 2024-2029 (%)
  • Exhibits94: Market opportunity by Indication ($ million)
  • Exhibits95: Data Table on Market opportunity by Indication ($ million)
  • Exhibits96: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits97: Chart on Market share By Geographical Landscape 2024-2029 (%)
  • Exhibits98: Data Table on Market share By Geographical Landscape 2024-2029 (%)
  • Exhibits99: Chart on Geographic comparison
  • Exhibits100: Data Table on Geographic comparison
  • Exhibits101: Chart on North America - Market size and forecast 2024-2029 ($ million)
  • Exhibits102: Data Table on North America - Market size and forecast 2024-2029 ($ million)
  • Exhibits103: Chart on North America - Year-over-year growth 2024-2029 (%)
  • Exhibits104: Data Table on North America - Year-over-year growth 2024-2029 (%)
  • Exhibits105: Chart on Europe - Market size and forecast 2024-2029 ($ million)
  • Exhibits106: Data Table on Europe - Market size and forecast 2024-2029 ($ million)
  • Exhibits107: Chart on Europe - Year-over-year growth 2024-2029 (%)
  • Exhibits108: Data Table on Europe - Year-over-year growth 2024-2029 (%)
  • Exhibits109: Chart on Asia - Market size and forecast 2024-2029 ($ million)
  • Exhibits110: Data Table on Asia - Market size and forecast 2024-2029 ($ million)
  • Exhibits111: Chart on Asia - Year-over-year growth 2024-2029 (%)
  • Exhibits112: Data Table on Asia - Year-over-year growth 2024-2029 (%)
  • Exhibits113: Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Exhibits114: Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Exhibits115: Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • Exhibits116: Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • Exhibits117: Chart on US - Market size and forecast 2024-2029 ($ million)
  • Exhibits118: Data Table on US - Market size and forecast 2024-2029 ($ million)
  • Exhibits119: Chart on US - Year-over-year growth 2024-2029 (%)
  • Exhibits120: Data Table on US - Year-over-year growth 2024-2029 (%)
  • Exhibits121: Chart on Germany - Market size and forecast 2024-2029 ($ million)
  • Exhibits122: Data Table on Germany - Market size and forecast 2024-2029 ($ million)
  • Exhibits123: Chart on Germany - Year-over-year growth 2024-2029 (%)
  • Exhibits124: Data Table on Germany - Year-over-year growth 2024-2029 (%)
  • Exhibits125: Chart on UK - Market size and forecast 2024-2029 ($ million)
  • Exhibits126: Data Table on UK - Market size and forecast 2024-2029 ($ million)
  • Exhibits127: Chart on UK - Year-over-year growth 2024-2029 (%)
  • Exhibits128: Data Table on UK - Year-over-year growth 2024-2029 (%)
  • Exhibits129: Chart on Canada - Market size and forecast 2024-2029 ($ million)
  • Exhibits130: Data Table on Canada - Market size and forecast 2024-2029 ($ million)
  • Exhibits131: Chart on Canada - Year-over-year growth 2024-2029 (%)
  • Exhibits132: Data Table on Canada - Year-over-year growth 2024-2029 (%)
  • Exhibits133: Chart on Japan - Market size and forecast 2024-2029 ($ million)
  • Exhibits134: Data Table on Japan - Market size and forecast 2024-2029 ($ million)
  • Exhibits135: Chart on Japan - Year-over-year growth 2024-2029 (%)
  • Exhibits136: Data Table on Japan - Year-over-year growth 2024-2029 (%)
  • Exhibits137: Chart on France - Market size and forecast 2024-2029 ($ million)
  • Exhibits138: Data Table on France - Market size and forecast 2024-2029 ($ million)
  • Exhibits139: Chart on France - Year-over-year growth 2024-2029 (%)
  • Exhibits140: Data Table on France - Year-over-year growth 2024-2029 (%)
  • Exhibits141: Chart on Brazil - Market size and forecast 2024-2029 ($ million)
  • Exhibits142: Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
  • Exhibits143: Chart on Brazil - Year-over-year growth 2024-2029 (%)
  • Exhibits144: Data Table on Brazil - Year-over-year growth 2024-2029 (%)
  • Exhibits145: Chart on China - Market size and forecast 2024-2029 ($ million)
  • Exhibits146: Data Table on China - Market size and forecast 2024-2029 ($ million)
  • Exhibits147: Chart on China - Year-over-year growth 2024-2029 (%)
  • Exhibits148: Data Table on China - Year-over-year growth 2024-2029 (%)
  • Exhibits149: Chart on India - Market size and forecast 2024-2029 ($ million)
  • Exhibits150: Data Table on India - Market size and forecast 2024-2029 ($ million)
  • Exhibits151: Chart on India - Year-over-year growth 2024-2029 (%)
  • Exhibits152: Data Table on India - Year-over-year growth 2024-2029 (%)
  • Exhibits153: Chart on Italy - Market size and forecast 2024-2029 ($ million)
  • Exhibits154: Data Table on Italy - Market size and forecast 2024-2029 ($ million)
  • Exhibits155: Chart on Italy - Year-over-year growth 2024-2029 (%)
  • Exhibits156: Data Table on Italy - Year-over-year growth 2024-2029 (%)
  • Exhibits157: Market opportunity By Geographical Landscape ($ million)
  • Exhibits158: Data Tables on Market opportunity By Geographical Landscape ($ million)
  • Exhibits159: Impact of drivers and challenges in 2024 and 2029
  • Exhibits160: Overview on criticality of inputs and factors of differentiation
  • Exhibits161: Overview on factors of disruption
  • Exhibits162: Impact of key risks on business
  • Exhibits163: Companies covered
  • Exhibits164: Company ranking index
  • Exhibits165: Matrix on companies position and classification
  • Exhibits166: Asana BioSciences LLC - Overview
  • Exhibits167: Asana BioSciences LLC - Product / Service
  • Exhibits168: Asana BioSciences LLC - Key offerings
  • Exhibits169: SWOT
  • Exhibits170: Bayer AG - Overview
  • Exhibits171: Bayer AG - Business segments
  • Exhibits172: Bayer AG - Key news
  • Exhibits173: Bayer AG - Key offerings
  • Exhibits174: Bayer AG - Segment focus
  • Exhibits175: SWOT
  • Exhibits176: BeiGene Ltd. - Overview
  • Exhibits177: BeiGene Ltd. - Business segments
  • Exhibits178: BeiGene Ltd. - Key offerings
  • Exhibits179: BeiGene Ltd. - Segment focus
  • Exhibits180: SWOT
  • Exhibits181: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits182: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits183: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits184: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits185: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits186: SWOT
  • Exhibits187: Fore Biotherapeutics - Overview
  • Exhibits188: Fore Biotherapeutics - Product / Service
  • Exhibits189: Fore Biotherapeutics - Key offerings
  • Exhibits190: SWOT
  • Exhibits191: Jazz Pharmaceuticals Plc - Overview
  • Exhibits192: Jazz Pharmaceuticals Plc - Product / Service
  • Exhibits193: Jazz Pharmaceuticals Plc - Key news
  • Exhibits194: Jazz Pharmaceuticals Plc - Key offerings
  • Exhibits195: SWOT
  • Exhibits196: Kinnate Biopharma Inc. - Overview
  • Exhibits197: Kinnate Biopharma Inc. - Product / Service
  • Exhibits198: Kinnate Biopharma Inc. - Key offerings
  • Exhibits199: SWOT
  • Exhibits200: Nerviano Medical Sciences S.r.l - Overview
  • Exhibits201: Nerviano Medical Sciences S.r.l - Product / Service
  • Exhibits202: Nerviano Medical Sciences S.r.l - Key offerings
  • Exhibits203: SWOT
  • Exhibits204: Novartis AG - Overview
  • Exhibits205: Novartis AG - Business segments
  • Exhibits206: Novartis AG - Key news
  • Exhibits207: Novartis AG - Key offerings
  • Exhibits208: Novartis AG - Segment focus
  • Exhibits209: SWOT
  • Exhibits210: Ono Pharmaceutical Co. Ltd. - Overview
  • Exhibits211: Ono Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits212: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits213: SWOT
  • Exhibits214: Pfizer Inc. - Overview
  • Exhibits215: Pfizer Inc. - Product / Service
  • Exhibits216: Pfizer Inc. - Key news
  • Exhibits217: Pfizer Inc. - Key offerings
  • Exhibits218: SWOT
  • Exhibits219: Pierre Fabre SA - Overview
  • Exhibits220: Pierre Fabre SA - Product / Service
  • Exhibits221: Pierre Fabre SA - Key offerings
  • Exhibits222: SWOT
  • Exhibits223: Inclusions checklist
  • Exhibits224: Exclusions checklist
  • Exhibits225: Currency conversion rates for US$
  • Exhibits226: Research methodology
  • Exhibits227: Information sources
  • Exhibits228: Data validation
  • Exhibits229: Validation techniques employed for market sizing
  • Exhibits230: Data synthesis
  • Exhibits231: 360 degree market analysis
  • Exhibits232: List of abbreviations
目次
Product Code: IRTNTR73550

The braf kinase inhibitors market is forecasted to grow by USD 2,162 mn during 2024-2029, accelerating at a CAGR of 9% during the forecast period. The report on the braf kinase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of braf kinase inhibitors, presence of patient assistance programs, and increasing prevalence of cancer.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 20258%
CAGR9%
Incremental Value$2,162 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's braf kinase inhibitors market is segmented as below:

By Product

    • Dabrafenib
    • Sorafenib
    • Vemurafenib
    • Encorafenib

By Distribution Channel

    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies

By Indication

    • Metastatic melanoma
    • Metastatic lung cancer
    • Others

By Geographical Landscape

    • North America
    • Europe
    • Asia
    • Rest of World (ROW)

This study identifies the expansion of research areas in braf kinase inhibitors as one of the prime reasons driving the braf kinase inhibitors market growth during the next few years. Also, growing strategic alliances and growing awareness of cancer will lead to sizable demand in the market.

The report on the braf kinase inhibitors market covers the following areas:

    • BRAF Kinase Inhibitors Market sizing
    • BRAF Kinase Inhibitors Market forecast
    • BRAF Kinase Inhibitors Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading braf kinase inhibitors market vendors that include Asana BioSciences LLC, Bayer AG, BeiGene Ltd., F. Hoffmann La Roche Ltd., Fore Biotherapeutics, Jazz Pharmaceuticals Plc, Kinnate Biopharma Inc., Nerviano Medical Sciences S.r.l, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Pierre Fabre SA. Also, the braf kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Global Market Characteristics
    • Executive Summary - Chart on Market By Geographical Landscape
    • Executive Summary - Chart on Market Segmentation by Product
    • Executive Summary - Chart on Market Segmentation by Distribution Channel
    • Executive Summary - Chart on Market Segmentation by Indication
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

  • 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • 2.2 Criticality of inputs and Factors of differentiation
    • Overview on criticality of inputs and factors of differentiation
  • 2.3 Factors of disruption
    • Overview on factors of disruption
  • 2.4 Impact of drivers and challenges
    • Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

  • 3.1 Market ecosystem
    • Parent Market
    • Data Table on - Parent Market
  • 3.2 Market characteristics
    • Market characteristics analysis
  • 3.3 Value chain analysis
    • Value chain analysis

4 Market Sizing

  • 4.1 Market definition
    • Offerings of companies included in the market definition
  • 4.2 Market segment analysis
    • Market segments
  • 4.3 Market size 2024
  • 4.4 Market outlook: Forecast for 2024-2029
    • Chart on Global - Market size and forecast 2024-2029 ($ million)
    • Data Table on Global - Market size and forecast 2024-2029 ($ million)
    • Chart on Global Market: Year-over-year growth 2024-2029 (%)
    • Data Table on Global Market: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

  • 5.1 Global BRAF Kinase Inhibitors Market 2019 - 2023
    • Historic Market Size - Data Table on Global BRAF Kinase Inhibitors Market 2019 - 2023 ($ million)
  • 5.2 Product segment analysis 2019 - 2023
    • Historic Market Size - Product Segment 2019 - 2023 ($ million)
  • 5.3 Distribution Channel segment analysis 2019 - 2023
    • Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
  • 5.4 Indication segment analysis 2019 - 2023
    • Historic Market Size - Indication Segment 2019 - 2023 ($ million)
  • 5.5 Geography segment analysis 2019 - 2023
    • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
  • 5.6 Country segment analysis 2019 - 2023
    • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

  • 6.1 The AI impact on Global BRAF Kinase Inhibitors Market

7 Five Forces Analysis

  • 7.1 Five forces summary
    • Five forces analysis - Comparison between 2024 and 2029
  • 7.2 Bargaining power of buyers
    • Bargaining power of buyers - Impact of key factors 2024 and 2029
  • 7.3 Bargaining power of suppliers
    • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
  • 7.4 Threat of new entrants
    • Threat of new entrants - Impact of key factors in 2024 and 2029
  • 7.5 Threat of substitutes
    • Threat of substitutes - Impact of key factors in 2024 and 2029
  • 7.6 Threat of rivalry
    • Threat of rivalry - Impact of key factors in 2024 and 2029
  • 7.7 Market condition
    • Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by Product

  • 8.1 Market segments
    • Chart on Product - Market share 2024-2029 (%)
    • Data Table on Product - Market share 2024-2029 (%)
  • 8.2 Comparison by Product
    • Chart on Comparison by Product
    • Data Table on Comparison by Product
  • 8.3 Dabrafenib - Market size and forecast 2024-2029
    • Chart on Dabrafenib - Market size and forecast 2024-2029 ($ million)
    • Data Table on Dabrafenib - Market size and forecast 2024-2029 ($ million)
    • Chart on Dabrafenib - Year-over-year growth 2024-2029 (%)
    • Data Table on Dabrafenib - Year-over-year growth 2024-2029 (%)
  • 8.4 Sorafenib - Market size and forecast 2024-2029
    • Chart on Sorafenib - Market size and forecast 2024-2029 ($ million)
    • Data Table on Sorafenib - Market size and forecast 2024-2029 ($ million)
    • Chart on Sorafenib - Year-over-year growth 2024-2029 (%)
    • Data Table on Sorafenib - Year-over-year growth 2024-2029 (%)
  • 8.5 Vemurafenib - Market size and forecast 2024-2029
    • Chart on Vemurafenib - Market size and forecast 2024-2029 ($ million)
    • Data Table on Vemurafenib - Market size and forecast 2024-2029 ($ million)
    • Chart on Vemurafenib - Year-over-year growth 2024-2029 (%)
    • Data Table on Vemurafenib - Year-over-year growth 2024-2029 (%)
  • 8.6 Encorafenib - Market size and forecast 2024-2029
    • Chart on Encorafenib - Market size and forecast 2024-2029 ($ million)
    • Data Table on Encorafenib - Market size and forecast 2024-2029 ($ million)
    • Chart on Encorafenib - Year-over-year growth 2024-2029 (%)
    • Data Table on Encorafenib - Year-over-year growth 2024-2029 (%)
  • 8.7 Market opportunity by Product
    • Market opportunity by Product ($ million)
    • Data Table on Market opportunity by Product ($ million)

9 Market Segmentation by Distribution Channel

  • 9.1 Market segments
    • Chart on Distribution Channel - Market share 2024-2029 (%)
    • Data Table on Distribution Channel - Market share 2024-2029 (%)
  • 9.2 Comparison by Distribution Channel
    • Chart on Comparison by Distribution Channel
    • Data Table on Comparison by Distribution Channel
  • 9.3 Hospital pharmacies - Market size and forecast 2024-2029
    • Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
    • Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
    • Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
    • Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
  • 9.4 Retail pharmacies - Market size and forecast 2024-2029
    • Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
    • Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
    • Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
    • Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
  • 9.5 Online pharmacies - Market size and forecast 2024-2029
    • Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
    • Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
    • Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
    • Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
  • 9.6 Market opportunity by Distribution Channel
    • Market opportunity by Distribution Channel ($ million)
    • Data Table on Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Indication

  • 10.1 Market segments
    • Chart on Indication - Market share 2024-2029 (%)
    • Data Table on Indication - Market share 2024-2029 (%)
  • 10.2 Comparison by Indication
    • Chart on Comparison by Indication
    • Data Table on Comparison by Indication
  • 10.3 Metastatic melanoma - Market size and forecast 2024-2029
    • Chart on Metastatic melanoma - Market size and forecast 2024-2029 ($ million)
    • Data Table on Metastatic melanoma - Market size and forecast 2024-2029 ($ million)
    • Chart on Metastatic melanoma - Year-over-year growth 2024-2029 (%)
    • Data Table on Metastatic melanoma - Year-over-year growth 2024-2029 (%)
  • 10.4 Metastatic lung cancer - Market size and forecast 2024-2029
    • Chart on Metastatic lung cancer - Market size and forecast 2024-2029 ($ million)
    • Data Table on Metastatic lung cancer - Market size and forecast 2024-2029 ($ million)
    • Chart on Metastatic lung cancer - Year-over-year growth 2024-2029 (%)
    • Data Table on Metastatic lung cancer - Year-over-year growth 2024-2029 (%)
  • 10.5 Others - Market size and forecast 2024-2029
    • Chart on Others - Market size and forecast 2024-2029 ($ million)
    • Data Table on Others - Market size and forecast 2024-2029 ($ million)
    • Chart on Others - Year-over-year growth 2024-2029 (%)
    • Data Table on Others - Year-over-year growth 2024-2029 (%)
  • 10.6 Market opportunity by Indication
    • Market opportunity by Indication ($ million)
    • Data Table on Market opportunity by Indication ($ million)

11 Customer Landscape

  • 11.1 Customer landscape overview
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

  • 12.1 Geographic segmentation
    • Chart on Market share By Geographical Landscape 2024-2029 (%)
    • Data Table on Market share By Geographical Landscape 2024-2029 (%)
  • 12.2 Geographic comparison
    • Chart on Geographic comparison
    • Data Table on Geographic comparison
  • 12.3 North America - Market size and forecast 2024-2029
    • Chart on North America - Market size and forecast 2024-2029 ($ million)
    • Data Table on North America - Market size and forecast 2024-2029 ($ million)
    • Chart on North America - Year-over-year growth 2024-2029 (%)
    • Data Table on North America - Year-over-year growth 2024-2029 (%)
  • 12.4 Europe - Market size and forecast 2024-2029
    • Chart on Europe - Market size and forecast 2024-2029 ($ million)
    • Data Table on Europe - Market size and forecast 2024-2029 ($ million)
    • Chart on Europe - Year-over-year growth 2024-2029 (%)
    • Data Table on Europe - Year-over-year growth 2024-2029 (%)
  • 12.5 Asia - Market size and forecast 2024-2029
    • Chart on Asia - Market size and forecast 2024-2029 ($ million)
    • Data Table on Asia - Market size and forecast 2024-2029 ($ million)
    • Chart on Asia - Year-over-year growth 2024-2029 (%)
    • Data Table on Asia - Year-over-year growth 2024-2029 (%)
  • 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
    • Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
    • Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
    • Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
    • Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • 12.7 US - Market size and forecast 2024-2029
    • Chart on US - Market size and forecast 2024-2029 ($ million)
    • Data Table on US - Market size and forecast 2024-2029 ($ million)
    • Chart on US - Year-over-year growth 2024-2029 (%)
    • Data Table on US - Year-over-year growth 2024-2029 (%)
  • 12.8 Germany - Market size and forecast 2024-2029
    • Chart on Germany - Market size and forecast 2024-2029 ($ million)
    • Data Table on Germany - Market size and forecast 2024-2029 ($ million)
    • Chart on Germany - Year-over-year growth 2024-2029 (%)
    • Data Table on Germany - Year-over-year growth 2024-2029 (%)
  • 12.9 UK - Market size and forecast 2024-2029
    • Chart on UK - Market size and forecast 2024-2029 ($ million)
    • Data Table on UK - Market size and forecast 2024-2029 ($ million)
    • Chart on UK - Year-over-year growth 2024-2029 (%)
    • Data Table on UK - Year-over-year growth 2024-2029 (%)
  • 12.10 Canada - Market size and forecast 2024-2029
    • Chart on Canada - Market size and forecast 2024-2029 ($ million)
    • Data Table on Canada - Market size and forecast 2024-2029 ($ million)
    • Chart on Canada - Year-over-year growth 2024-2029 (%)
    • Data Table on Canada - Year-over-year growth 2024-2029 (%)
  • 12.11 Japan - Market size and forecast 2024-2029
    • Chart on Japan - Market size and forecast 2024-2029 ($ million)
    • Data Table on Japan - Market size and forecast 2024-2029 ($ million)
    • Chart on Japan - Year-over-year growth 2024-2029 (%)
    • Data Table on Japan - Year-over-year growth 2024-2029 (%)
  • 12.12 France - Market size and forecast 2024-2029
    • Chart on France - Market size and forecast 2024-2029 ($ million)
    • Data Table on France - Market size and forecast 2024-2029 ($ million)
    • Chart on France - Year-over-year growth 2024-2029 (%)
    • Data Table on France - Year-over-year growth 2024-2029 (%)
  • 12.13 Brazil - Market size and forecast 2024-2029
    • Chart on Brazil - Market size and forecast 2024-2029 ($ million)
    • Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
    • Chart on Brazil - Year-over-year growth 2024-2029 (%)
    • Data Table on Brazil - Year-over-year growth 2024-2029 (%)
  • 12.14 China - Market size and forecast 2024-2029
    • Chart on China - Market size and forecast 2024-2029 ($ million)
    • Data Table on China - Market size and forecast 2024-2029 ($ million)
    • Chart on China - Year-over-year growth 2024-2029 (%)
    • Data Table on China - Year-over-year growth 2024-2029 (%)
  • 12.15 India - Market size and forecast 2024-2029
    • Chart on India - Market size and forecast 2024-2029 ($ million)
    • Data Table on India - Market size and forecast 2024-2029 ($ million)
    • Chart on India - Year-over-year growth 2024-2029 (%)
    • Data Table on India - Year-over-year growth 2024-2029 (%)
  • 12.16 Italy - Market size and forecast 2024-2029
    • Chart on Italy - Market size and forecast 2024-2029 ($ million)
    • Data Table on Italy - Market size and forecast 2024-2029 ($ million)
    • Chart on Italy - Year-over-year growth 2024-2029 (%)
    • Data Table on Italy - Year-over-year growth 2024-2029 (%)
  • 12.17 Market opportunity By Geographical Landscape
    • Market opportunity By Geographical Landscape ($ million)
    • Data Tables on Market opportunity By Geographical Landscape ($ million)

13 Drivers, Challenges, and Opportunity/Restraints

  • 13.1 Market drivers
  • 13.2 Market challenges
  • 13.3 Impact of drivers and challenges
    • Impact of drivers and challenges in 2024 and 2029
  • 13.4 Market opportunities/restraints

14 Competitive Landscape

  • 14.1 Overview
  • 14.2 Competitive Landscape
    • Overview on criticality of inputs and factors of differentiation
  • 14.3 Landscape disruption
    • Overview on factors of disruption
  • 14.4 Industry risks
    • Impact of key risks on business

15 Competitive Analysis

  • 15.1 Companies profiled
    • Companies covered
  • 15.2 Company ranking index
    • Company ranking index
  • 15.3 Market positioning of companies
    • Matrix on companies position and classification
  • 15.4 Asana BioSciences LLC
    • Asana BioSciences LLC - Overview
    • Asana BioSciences LLC - Product / Service
    • Asana BioSciences LLC - Key offerings
    • SWOT
  • 15.5 Bayer AG
    • Bayer AG - Overview
    • Bayer AG - Business segments
    • Bayer AG - Key news
    • Bayer AG - Key offerings
    • Bayer AG - Segment focus
    • SWOT
  • 15.6 BeiGene Ltd.
    • BeiGene Ltd. - Overview
    • BeiGene Ltd. - Business segments
    • BeiGene Ltd. - Key offerings
    • BeiGene Ltd. - Segment focus
    • SWOT
  • 15.7 F. Hoffmann La Roche Ltd.
    • F. Hoffmann La Roche Ltd. - Overview
    • F. Hoffmann La Roche Ltd. - Business segments
    • F. Hoffmann La Roche Ltd. - Key news
    • F. Hoffmann La Roche Ltd. - Key offerings
    • F. Hoffmann La Roche Ltd. - Segment focus
    • SWOT
  • 15.8 Fore Biotherapeutics
    • Fore Biotherapeutics - Overview
    • Fore Biotherapeutics - Product / Service
    • Fore Biotherapeutics - Key offerings
    • SWOT
  • 15.9 Jazz Pharmaceuticals Plc
    • Jazz Pharmaceuticals Plc - Overview
    • Jazz Pharmaceuticals Plc - Product / Service
    • Jazz Pharmaceuticals Plc - Key news
    • Jazz Pharmaceuticals Plc - Key offerings
    • SWOT
  • 15.10 Kinnate Biopharma Inc.
    • Kinnate Biopharma Inc. - Overview
    • Kinnate Biopharma Inc. - Product / Service
    • Kinnate Biopharma Inc. - Key offerings
    • SWOT
  • 15.11 Nerviano Medical Sciences S.r.l
    • Nerviano Medical Sciences S.r.l - Overview
    • Nerviano Medical Sciences S.r.l - Product / Service
    • Nerviano Medical Sciences S.r.l - Key offerings
    • SWOT
  • 15.12 Novartis AG
    • Novartis AG - Overview
    • Novartis AG - Business segments
    • Novartis AG - Key news
    • Novartis AG - Key offerings
    • Novartis AG - Segment focus
    • SWOT
  • 15.13 Ono Pharmaceutical Co. Ltd.
    • Ono Pharmaceutical Co. Ltd. - Overview
    • Ono Pharmaceutical Co. Ltd. - Product / Service
    • Ono Pharmaceutical Co. Ltd. - Key offerings
    • SWOT
  • 15.14 Pfizer Inc.
    • Pfizer Inc. - Overview
    • Pfizer Inc. - Product / Service
    • Pfizer Inc. - Key news
    • Pfizer Inc. - Key offerings
    • SWOT
  • 15.15 Pierre Fabre SA
    • Pierre Fabre SA - Overview
    • Pierre Fabre SA - Product / Service
    • Pierre Fabre SA - Key offerings
    • SWOT

16 Appendix

  • 16.1 Scope of the report
  • 16.2 Inclusions and exclusions checklist
    • Inclusions checklist
    • Exclusions checklist
  • 16.3 Currency conversion rates for US$
    • Currency conversion rates for US$
  • 16.4 Research methodology
    • Research methodology
  • 16.5 Data procurement
    • Information sources
  • 16.6 Data validation
    • Data validation
  • 16.7 Validation techniques employed for market sizing
    • Validation techniques employed for market sizing
  • 16.8 Data synthesis
    • Data synthesis
  • 16.9 360 degree market analysis
    • 360 degree market analysis
  • 16.10 List of abbreviations
    • List of abbreviations